SK Biopharmaceuticals Co., Ltd.
326030
Rang în acțiuni
#4038
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Preț acțiune
$51.65
Capitalizare de piață
$4.05B
Schimbare (1 zi)
0.27%
Schimbare (1 an)
-30.95%
Țară
KR
Tranzacționează SK Biopharmaceuticals Co., Ltd. (326030)
Categorie
Healthcare
Raport P/S pentru SK Biopharmaceuticals Co., Ltd. (326030)
Raport P/S la data de October 2026 TTM: 6.31
Conform celor mai recente rapoarte financiare și prețului acțiunilor SK Biopharmaceuticals Co., Ltd., raportul P/S actual (TTM) este 6.31. La sfârșitul anului 2024, compania avea un P/S de 15.89.
Istoricul raportului P/S pentru SK Biopharmaceuticals Co., Ltd. din 2011 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 6.31 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 15.89 | -30.16% |
| 2023 | 22.75 | 0.17% |
| 2022 | 22.71 | 24.92% |
| 2021 | 18.18 | -96.10% |
| 2020 | 466.49 | 599.92% |
| 2019 | 66.65 | -99.07% |
| 2018 | 7.19K | 9,564.87% |
| 2017 | 74.43 | 5.37% |
| 2016 | 70.64 | -20.55% |
| 2015 | 88.91 | 2.53% |
| 2014 | 86.72 | 3.20% |
| 2013 | 84.03 | -14.35% |
| 2012 | 98.11 | -27.27% |
| 2011 | 134.89 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | 58.83% |
US
|
|
| 40.55 | 542.65% |
US
|
|
| 3.96 | -37.22% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 60.80% |
NL
|
